There used to be a time in medicine when patients were generally expected to project a cheerful disposition during ward rounds. This is coupled with a belief in the literal interpretation of the biblical adage “a joyful heart is good medicine” and that being generally optimistic about one’s health can play a role in faster…
MRI is a useful tool in the management of NMOSD, from diagnosis to disease monitoring and treatment decision-making.
Researchers have recently explored the global epidemiological picture of neuromyelitis optica spectrum disorder from various angles.
We review current (and future) therapies for neuromyelitis optica spectrum disorder and discuss how the treatment landscape Is changing.
With the updated definition of neuromyelitis optica spectrum disorder in 2015, studies have estimated a rise of around 1.5 fold in disease prevalence.
We compare the most common types of first-line immunosuppressants currently used to treat neuromyelitis optica spectrum disorder (NMOSD).
Researchers are investigating anecdotal reports of NMOSD relapse associated with COVID-19 vaccines and examining the science behind them.
In the management of any disease in which relapses are known to occur, it is important to identify the risk factors for their occurrence, as well as any other factors that might influence their severity. In this article, we will be assessing the risk factors for relapse in patients with neuromyelitis optica spectrum disorder (NMOSD)…
We explore the efficacy and mechanisms of 3 immunosuppressive therapies that have been approved for use in neuromyelitis optica spectrum disorder (NMOSD).
Investigators strove to quantify imaging patterns of central nervous system damage in MOGAD during the remission stage, and to compare it with NMOSD-AQP4 and MS.
Please login or register first to view this content.
